Correlation between SV2A expression in tumour tissue and efficacy of levetiracetam in glioma patients with epilepsy.

• Conditions: epilepsy; seizures; 10039911

• Registration Number: NL-OMON30525
• Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

We will include adult (> 18 years) glioma patients who suffered from partial seizures, with or without secondary generalisation, preoperatively. Patients must have undergone surgery for their newly-diagnosed or recurrent glioma not more than 42 days previously and be treated with levetiracetam monotherapy at the time of inclusion.

Exclusion Criteria

Patients who do not have a basic proficiency of the Dutch language, or are unable to communicate adequately (e.g. due to dysphasia) will be excluded.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary study parameter is the total number of seizures during the study<br /><br>period, which is 6 months for every indivicual patient.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The secondary study parameters will be time to drug withdrawal due to<br /><br>inadequate seizure control (if applicable). Other study parameters will be<br /><br>change in cognitive function, quality of life, and brain activity as measured<br /><br>by MEG at the end of the study, compared with baseline.</p><br>